This study aims to demonstrate the superiority of budesonide compared to placebo as
maintenance therapy in keeping patients in remission over a one-year period
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Collaborator:
The Swedish Organization for Studies on Inflammatory Bowel Disease